Showing results (121-130 of 297) with videos related to
Sort By:
Pageof 30
AIDS Care|June 27, 2019
Female adherence self-efficacy before and after couple HIV testing and counseling within Malawi's Option B+ programAustin Wesevich, Mina C Hosseinipour, Carol E Golin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumorsM Eileen Dolan, Mitchell Posner, Theodore Karrison, et al.Journal of Clinical Pharmacology|October 14, 2021
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose DeescalationCody J Peer, Brian L Heiss, Daniel A Goldstein, et al.Cancer Chemotherapy and Pharmacology|March 27, 2002
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient miceLalitha Iyer, Jacqueline Ramírez, Dale R Shepard, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 2007
Lack of association between common polymorphisms in UGT1A9 and gene expression and activityJacqueline Ramírez, Wanqing Liu, Snezana Mirkov, et al.JCO Oncology Practice|July 14, 2023
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas EmissionsSofia I Jacobson, Alec J Kacew, Randall W Knoebel, et al.AIDS Research and Therapy|June 12, 2023
Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option BMaganizo B Chagomerana, Bryna J Harrington, Bethany L DiPrete, et al.Cancer Research|January 25, 2005
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoterWanqing Liu, Federico Innocenti, Michael H Wu, et al.Pharmacogenetics|December 5, 2002
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groupsFederico Innocenti, Carrie Grimsley, Soma Das, et al.Cancer Chemotherapy and Pharmacology|July 6, 2004
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancerApurva A Desai, Federico Innocenti, Linda Janisch, et al.Pageof 30